Workflow
Banco Santander(SAN)
icon
Search documents
21独家|外资银行加码大湾区,桑坦德将“借力”城商行落子深圳
南方财经记者 黄子潇 深圳报道 近日,桑坦德银行正式获批筹建深圳分行,第三次落子中国内地。 此前,这家西班牙最大的银行已设立上海分行、北京分行,不过尚未在内地注册为法人银行,在展业上 受到一定限制。 过去,桑坦德银行选择与上海银行、北京银行等城商行合作,以开拓中国市场。 如今,其深圳分行获批后,业务定位如何、是否寻求当地银行的合作、如何切入深圳市场等,均是值得 探究的问题。 21世纪经济报道记者独家获悉,桑坦德银行深圳分行将延续前述本地化策略,利用母行的全球网络优势 服务境内企业出海,而与一家头部城商行深圳分行的合作将成为关键一环。 "双方经营区域高度重叠,但经营侧重仍各有不同,有着天然的互补性。"相关人士向21世纪经济报道记 者介绍。 延续城商行合作模式 非法人银行的业务范围受到限制。过去,桑坦德银行选择了与北京银行、上海银行合作,借助这些城商 行的本地网络切入中国市场。而记者独家了解到,这一做法也将在深圳延续。 服务湾区企业出海 去年12月,21世纪经济报道曾报道,西班牙桑坦德银行董事会已决策通过在深圳设立分行,为西语国家 公民和西语国家企业提供金融服务。同月,该行在深圳全球招商大会上与当地政府正式签约。 ...
Why Banco Santander (SAN) is a Top Dividend Stock for Your Portfolio
ZACKS· 2025-07-11 16:45
Company Overview - Banco Santander (SAN) is based in Madrid and operates in the Finance sector, with shares experiencing a price change of 88.16% this year [3] - The company currently pays a dividend of $0.09 per share, resulting in a dividend yield of 2.11%, which is lower than the Banks - Foreign industry's yield of 3.33% and the S&P 500's yield of 1.52% [3] Dividend Performance - The current annualized dividend of Banco Santander is $0.18, reflecting a 20% increase from the previous year [4] - Over the past 5 years, the company has increased its dividend 4 times year-over-year, averaging an annual increase of 35.07% [4] - The current payout ratio is 18%, indicating that the company paid out 18% of its trailing 12-month earnings per share as dividends [4] Earnings Expectations - The Zacks Consensus Estimate for Banco Santander's earnings in 2025 is $0.97 per share, with an expected increase of 16.87% from the previous year [5] Investment Considerations - Income investors favor dividends for enhancing stock investing profits, reducing overall portfolio risk, and providing tax advantages [5] - High-growth firms or tech start-ups typically do not offer dividends, while larger, established companies are viewed as better dividend options [6] - Banco Santander is considered a compelling investment opportunity due to its strong dividend profile and current Zacks Rank of 3 (Hold) [6]
Sanofi: Information concerning the total number of voting rights and shares - June 2025
Globenewswire· 2025-07-09 16:29
Core Points - The document provides information regarding the total number of voting rights and shares of Sanofi as of June 30, 2025 [1] - Sanofi has a registered share capital of €2,452,461,656 [1] Summary by Category Voting Rights and Shares - Total number of issued shares is 1,227,756,274 [1] - The number of real voting rights, excluding treasury shares, is 1,351,296,496 [1] - The theoretical number of voting rights, including treasury shares, is 1,361,952,562 [1]
西班牙桑坦德银行深圳分行获批筹建,外资金融版图再扩容
Nan Fang Du Shi Bao· 2025-07-08 12:00
近日,国家金融监督管理总局正式批复同意西班牙桑坦德银行在深圳筹建分行,这意味着深圳即将迎来 又一家欧资银行,外资金融机构在深"朋友圈"持续扩容。 作为西班牙最大的商业银行,桑坦德银行自1857年成立以来,已发展成为全球系统重要性银行之一,业 务版图横跨欧洲、拉丁美洲、美国及亚太地区,核心市场覆盖西班牙、葡萄牙、英国、美国、墨西哥等 多个国家。截至2024年末,其总资产达1.8万亿欧元,全年总收入618.76亿欧元,净利润137.44亿欧元。 值得关注的是,此次在深设分行,是桑坦德银行继2008年上海分行、2014年北京分行后,时隔十年再次 布局中国。 西班牙桑坦德银行落子深圳,外资加码共享发展红利 桑坦德银行与中国的渊源可追溯至2008年上海分行的设立,2014年北京分行开业后,该行在华业务逐步 覆盖企业银行、环球市场及财富管理等领域。此次时隔十年,桑坦德银行再次在华设分行,恰逢中国金 融开放关键期。自2018年以来,金融管理部门先后出台50余项对外开放措施,从取消银行、证券、基金 管理等领域外资持股比例限制,到在企业征信、评级、支付等领域给予外资机构国民待遇,再到放宽资 产规模、经营年限等股东资质要求,一系 ...
Credit Agricole Sa: Crédit Agricole S.A. completes the acquisition of Santander’s 30.5% stake in CACEIS and now brings its ownership to 100%
Globenewswire· 2025-07-04 15:45
Group 1 - Crédit Agricole S.A. has completed the acquisition of Santander's 30.5% stake in CACEIS, bringing its ownership to 100% [1] - This acquisition strengthens Crédit Agricole's position in CACEIS, a significant player in the European asset servicing market, and supports the group's strategic development in this business [2] - The transaction aligns with Crédit Agricole Group's investment return targets but will negatively impact the fully-loaded CET1 ratio by approximately 30 basis points [3]
Adagene announces up to $25 million strategic investment from Sanofi
Globenewswire· 2025-07-01 11:00
Core Insights - Sanofi has made a strategic investment of up to US$25 million in Adagene to support the development of novel antibody-based therapies, particularly focusing on the clinical development of muzastotug (ADG126) for colorectal cancer [3][6] - Adagene will provide Sanofi with muzastotug for a phase 1/2 clinical trial involving over 100 patients to evaluate its safety and efficacy in combination with other anticancer therapies [4][6] - The partnership includes the exercise of an option for a third SAFEbody discovery program, which will utilize Adagene's proprietary technology [5][6] Financial Overview - The proceeds from Sanofi's investment, along with Adagene's existing cash and cash equivalents of US$85.2 million as of December 31, 2024, are expected to fund operations into 2027 [6] Clinical Development - Adagene's lead clinical program, ADG126, is currently in phase 1b/2 studies, targeting metastatic microsatellite-stable colorectal cancer [10] - The SAFEbody technology aims to enhance safety and tolerability in antibody therapeutics by using precision masking to minimize off-target toxicity [9][10] Strategic Collaboration - A representative from Sanofi will join Adagene's Scientific Advisory Board to provide strategic advice on scientific and clinical aspects [7] - The collaboration reinforces the shared vision of advancing ADG126's potential in treating advanced solid tumors [6]
Press release: Availability of the Q2 2025 Aide mémoire
Globenewswire· 2025-06-30 05:30
Core Insights - Sanofi has made its Q2 2025 Aide mémoire available on its website to assist in financial modeling of the Group's quarterly results, with the official results set to be published on July 31, 2025 [1] - The company is focused on R&D and utilizes AI to develop medicines and vaccines, aiming to address urgent healthcare challenges and improve lives globally [2] Company Overview - Sanofi is listed on both EURONEXT and NASDAQ, indicating its presence in major financial markets [3] - The company emphasizes its commitment to innovation and societal impact through its research and development efforts [2]
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
Globenewswire· 2025-06-30 05:00
Core Insights - The Japanese Ministry of Health, Labour and Welfare has granted orphan drug designation to riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP), highlighting its potential to address significant unmet medical needs in this rare neurological condition [1][5] - Approximately 30% of CIDP patients do not respond to standard therapies, and many who do experience incomplete responses, indicating a substantial market opportunity for riliprubart [3][5] Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, leveraging a deep understanding of the immune system [4] - The company is currently conducting two phase 3 studies for riliprubart, aiming to establish it as a first-in-class treatment for CIDP [5] Product Development - Riliprubart (SAR445088) is a humanized IgG4 monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway, potentially reducing inflammation and preventing nerve damage in CIDP [3] - Long-term efficacy and safety data from a phase 2 study of riliprubart were presented, suggesting sustained benefits for CIDP patients [2] Market Context - There are approximately 4,000 diagnosed CIDP patients in Japan, with a significant portion experiencing debilitating symptoms despite existing therapies [1][3] - The orphan drug designation in Japan adds to similar recognitions in the US and Europe, reinforcing the global regulatory acknowledgment of riliprubart's potential [5]
Banco Santander (SAN) is a Top Dividend Stock Right Now: Should You Buy?
ZACKS· 2025-06-25 16:51
Group 1: Company Overview - Banco Santander (SAN) is based in Madrid and operates in the Finance sector, with shares experiencing a price change of 81.36% this year [3] - The company currently pays a dividend of $0.09 per share, resulting in a dividend yield of 2.19%, which is lower than the Banks - Foreign industry's yield of 3.4% and the S&P 500's yield of 1.6% [3] Group 2: Dividend Performance - Banco Santander's annualized dividend of $0.18 has increased by 20% from the previous year, with an average annual increase of 17.90% over the last 5 years [4] - The current payout ratio is 18%, indicating that the company paid out 18% of its trailing 12-month earnings per share as dividends [4] Group 3: Earnings Growth - The Zacks Consensus Estimate for Banco Santander's earnings in 2025 is $0.97 per share, with an expected increase of 16.87% from the previous year [5] Group 4: Investment Considerations - Dividends are favored by investors for various reasons, including tax advantages and risk reduction, although not all companies provide quarterly payouts [6] - Banco Santander is considered a compelling investment opportunity due to its strong dividend performance and current Zacks Rank of 3 (Hold) [7]
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Globenewswire· 2025-06-25 05:00
Core Insights - The FDA has granted orphan drug designation to riliprubart for treating antibody-mediated rejection (AMR) in solid organ transplantation, highlighting a significant unmet need in transplant medicine [1][2] - Riliprubart is a first-in-class IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway [3] - Sanofi is conducting multiple clinical studies for riliprubart, including a phase 2 study for kidney transplant recipients and two phase 3 studies for chronic inflammatory demyelinating polyneuropathy [2][6] Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, leveraging deep understanding of the immune system [5] - The company is committed to addressing urgent healthcare challenges and has a robust pipeline aimed at high unmet medical needs [5] Industry Context - Antibody-mediated rejection is a serious complication post-organ transplantation, where the recipient's immune system attacks the transplanted organ, leading to potential organ failure if untreated [4] - The orphan drug designation reflects the rarity of the condition, affecting fewer than 200,000 people in the US, and underscores the importance of developing targeted therapies in this area [1][4]